ALIM - Alimera Sciences GAAP EPS of -$1.32 misses by $1.33 revenue of $17.5M misses by $2.95M
2023-08-10 07:37:20 ET
- Alimera Sciences press release ( NASDAQ: ALIM ): Q2 GAAP EPS of -$1.32 misses by $1.33 .
- Revenue of $17.5M (+19.9% Y/Y) misses by $2.95M .
- The increase was primarily due to the addition of YUTIQ into the U.S. portfolio. Global end user demand for ILUVIEN in Q2 2023 was 2,601 units, up 13.5% compared to Q2 2022. In addition, YUTIQ generated an additional 440 units of end user demand in the second quarter from the date of acquisition in late May.
- Net loss of $10.7 million versus $3.1 million in Q2 2022 driven primarily by cost associated with financings this year
For further details see:
Alimera Sciences GAAP EPS of -$1.32 misses by $1.33, revenue of $17.5M misses by $2.95M